METTL3 and myeloid leukemia: These results suggest that genetic alterations of m6A regulatory genes in cooperation with TP53 contribute to the pathogenesis and maintenance of AML, and provide a rationale for therapeutic targeting of METTL3 in myeloid leukemia.